SRC and Miyoshi myopathy: Moreover, a prolonged exposure of MM endothelial cells to dasatinib, an oral bioactive PDGFRβ/Src tyrosine kinase inhibitor, annulled their ability to respond to VEGF, preventing the expression of endogenous VEGF in a time-dependent manner, and the levels of secreted VEGF in the conditioned medium of MM endothelial cells in a dose-dependent manner.